Your browser doesn't support javascript.
loading
Definition and measurement of post-COVID-19 conditions in real-world practice: a global systematic literature review.
Yang, Jingyan; Markus, Kristen; Andersen, Kathleen Michelle; Rudolph, Abby E; McGrath, Leah J; Nguyen, Jennifer L; Kyaw, Moe H; Whittle, Isabelle; Blazos, Vasileios; Heron, Louise; Spinardi, Julia Regazzini.
Afiliação
  • Yang J; Pfizer Inc, New York, New York, USA jingyan.yang@pfizer.com.
  • Markus K; Institute for Social and Economic Research and Policy, Columbia University, New York, New York, USA.
  • Andersen KM; Adelphi Values PROVE, Bollington, UK.
  • Rudolph AE; Pfizer Inc, New York, New York, USA.
  • McGrath LJ; Pfizer Inc, New York, New York, USA.
  • Nguyen JL; Pfizer Inc, New York, New York, USA.
  • Kyaw MH; Pfizer Inc, New York, New York, USA.
  • Whittle I; Pfizer Inc, New York, New York, USA.
  • Blazos V; Adelphi Values PROVE, Bollington, UK.
  • Heron L; Adelphi Values PROVE, Bollington, UK.
  • Spinardi JR; Adelphi Values PROVE, Bollington, UK.
BMJ Open ; 14(1): e077886, 2024 01 17.
Article em En | MEDLINE | ID: mdl-38233057
ABSTRACT
Post-COVID-19 conditions (PCC) is an umbrella term that encompasses a range of signs, symptoms and conditions present weeks after the acute phase of a SARS-CoV-2 infection. This systematic literature review summarises the heterogeneous methodology used to measure PCC across real-world studies and highlights trends by region, age group, PCC follow-up period and data source.

METHODS:

Medline, EMBASE and the Cochrane Library were searched and supplemented with conference and grey literature searches. Eligible studies included individuals with (1) PCC or (2) a positive SARS-CoV-2 test or COVID-19 diagnosis who were followed over time. Included studies were published in English between 1 January 2020 and 14 November 2022.

FINDINGS:

Of 291 publications included, 175 (60%) followed individuals with confirmed COVID-19 over time for PCC and 116 (40%) used a prespecified PCC definition. There was substantial heterogeneity in study design, geography, age group, PCC conditions/symptoms assessed and their classification and duration of follow-up. Among studies using a prespecified PCC definition, author-defined criteria (51%) were more common than criteria recommended by major public health organisations (19%). Measurement periods for PCC outcomes from date of acute COVID-19 test were primarily 3 to <6 months (39.2%), followed by 6 to <12 months (27.5%) and <3 months (22.9%). When classified by organ/system, constitutional-related PCC were the most frequently assessed in adult (86%) and paediatric (87%) populations. Within constitutional symptoms, fatigue was most frequently assessed in adult (91.6%) and paediatric (95.0%) populations, followed by fever/chills (37.9% and 55%, respectively).

CONCLUSIONS:

PCC definitions are heterogenous across real-world studies, which limits reliable comparisons between studies. However, some similarities were observed in terms of the most frequently measured PCC-associated symptoms/conditions, which may aid clinical management of patients with PCC.CRD42022376111.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article